{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:37:30Z","timestamp":1783633050517,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>To evaluate association of carcinoid syndrome (CS) symptom burden and somatostatin analog (SSA) duration with quality of life (QoL) using Functional Assessment of Cancer Therapy-General (FACT-G) and Patient-Reported Outcomes Measurement Information System (PROMIS-29) instruments.<\/jats:p>\n            <jats:p>Adults who received treatment for CS symptoms in the US were recruited to participate in a cross-sectional online survey (July\u2013October, 2016). Demographic, clinical, and QoL questions (FACT-G, 29 CS-related supplemental questions, PROMIS-29) were included. Descriptive and multivariable regression analyses adjusting for demographic and clinical characteristics followed.<\/jats:p>\n            <jats:p>Most (98%) of the 117 patients received SSAs in the prior month. Multivariable regression analysis showed \u22654 bowel movements\/day (vs &lt;4) and each additional CS symptom was associated with 7.1 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.043) and 3.4 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.034) point FACT-G total score decreases, respectively. Requiring bed rest (vs normal activity) was associated with significant decreases in FACT-G total score (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). There were similar associations for FACT-G subscales, supplemental questions, and PROMIS-29. After adjustment, FACT-G total score was significantly higher (11.3 points; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.033) for patients treated with SSA &gt;8 years versus &lt;2.7 years.<\/jats:p>\n            <jats:p>CS symptom burden was observed to be associated with lower QoL scores, measured by FACT-G. Patients with &gt;8 years SSA treatment duration versus &lt;2.7 years had higher QoL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013390","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T04:27:05Z","timestamp":1542774425000},"page":"e13390","source":"Crossref","is-referenced-by-count":10,"title":["Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome"],"prefix":"10.1097","volume":"97","author":[{"given":"Daniel M.","family":"Halperin","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL"},{"name":"Terasaki Research Institute, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Cai","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor","family":"Totev","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Bhak","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei S.","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P.","family":"Neary","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","article-title":"Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"241","DOI":"10.6004\/jnccn.2016.0029","article-title":"Somatostatin analogues in neuroendocrine tumors","volume":"14","author":"Kulke","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11136-009-9487-x","article-title":"Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population","volume":"18","author":"Haugland","year":"2009","journal-title":"Qual Life Res"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Frojd","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s00520-016-3189-z","article-title":"Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden","volume":"24","author":"Pearman","year":"2016","journal-title":"Support Care Cancer"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"R12-20230914","first-page":"604","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Quality Life Res"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","article-title":"Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Pavel","year":"2017","journal-title":"Lancet Oncol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10555-015-9573-1","article-title":"Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors","volume":"34","author":"Jimenez-Fonseca","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2796.1995.tb01175.x","article-title":"Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial","volume":"237","author":"Jacobsen","year":"1995","journal-title":"J Intern Med"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12955-016-0527-2","article-title":"Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours","volume":"14","author":"Martini","year":"2016","journal-title":"Health Qual Life Outcomes"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811210-00060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:19:29Z","timestamp":1694711969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811210-00060"}},"subtitle":["A survey study"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":18,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013390","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}